Site Search
Professionals 146 results
Capabilities 33 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies
involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have
technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a uniq...Read more
involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have
technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a uniq...Read more
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience
to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances
and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances
and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic
fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility,
drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable ...Read more
fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility,
drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable ...Read more
Experience 10 results
Experience
|February 12, 2024
Experience
|December 20, 2021
ACON Investments’ Acquisition of Vitalis Group
Winston & Strawn LLP represented ACON LatAm Management, L.L.C.; ACON Latin America Opportunities Fund V, L.P.; and certain of their respective affiliates
in the acquisitions of the companies that form the Vitalis Group (Vitalis), a leading manufacturer and wholesaler of generic injectable pharmaceuticals with
production facilities in Colombia and Mexico, with sales to more than 20 countries, mainly in Latin America. Vitalis is representative of ACON’s La...Read more
in the acquisitions of the companies that form the Vitalis Group (Vitalis), a leading manufacturer and wholesaler of generic injectable pharmaceuticals with
production facilities in Colombia and Mexico, with sales to more than 20 countries, mainly in Latin America. Vitalis is representative of ACON’s La...Read more
Experience
|December 15, 2021
Arbor Investments’ Acquisition of Oregon Freeze Dry
Winston & Strawn LLP represented Arbor Investments, a specialized private equity firm that focuses exclusively on investing in food, beverage, and related
industries, in its acquisition of Oregon Freeze Dry (“OFD” or the “Company”) from Endeavour Capital. OFD is North America’s largest and most technologically
advanced freeze-dryer of food, probiotics, enzymes, proteins, specialty ingredients, and lyophilized pharmaceutical inputs. With nearly six decad...Read more
industries, in its acquisition of Oregon Freeze Dry (“OFD” or the “Company”) from Endeavour Capital. OFD is North America’s largest and most technologically
advanced freeze-dryer of food, probiotics, enzymes, proteins, specialty ingredients, and lyophilized pharmaceutical inputs. With nearly six decad...Read more
Insights & News 297 results
Webinar
|July 15, 2025
The Revival of Most-Favored-Nation Pricing: What Pharma Needs to Know
Join us for a webinar exploring the evolving antitrust landscape as it intersects with drug pricing policy and regulation under the current administration.
Reviving the “most-favored-nation” drug pricing principle of the prior Trump administration, this administration is leveraging antitrust tools to address high
pharmaceutical costs, signaling a shift toward increased regulatory scrutiny of market power and pricing disparities. Our attorneys will cover the ...Read more
Reviving the “most-favored-nation” drug pricing principle of the prior Trump administration, this administration is leveraging antitrust tools to address high
pharmaceutical costs, signaling a shift toward increased regulatory scrutiny of market power and pricing disparities. Our attorneys will cover the ...Read more
Client Alert
|July 7, 2025
|4 Min Read
On June 11, 2025, Assistant Attorney General Brett Shumate issued a memorandum to all U.S. Department of Justice Civil Division employees outlining enforcement priorities under directives from President Trump and Attorney General Bondi. The Memorandum signals a shift in federal enforcement focus to issues such as discrimination, gender transition care, and immigration, and identifies the False Claims Act as a tool to achieve certain of the Administration’s goals.
Press Release
|June 24, 2025
|1 Min Read
Winston & Strawn Expands Restructuring Practice with Addition of Jonathan Levine in New York
NEW YORK – June 24, 2025 – Winston & Strawn LLP announced today that Jonathan Levine has joined its New York office as a partner in the firm’s
Transactions Department and a member of the Restructuring Practice.
Transactions Department and a member of the Restructuring Practice.
Other Results 27 results
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons
and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For
example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—...Read more
and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For
example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—...Read more
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service
Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein
(except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent org...Read more
Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein
(except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent org...Read more
Law Glossary
How Does an Applicant Establish Biosimilarity?
An applicant typically demonstrates biosimilarity based on non-clinical analyses that focus on the structure and functional differences between the biosimilar
and reference product.
and reference product.